MedTrace Logo

Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab

NCT05614752 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10067

Last updated 2025-01-24

No results posted yet for this study

Summary

This observational study is a large-scale, prospective, and multi-institutional observational study.

Patients from 19 to 75 years of age, will take a self-assessment (PRO) during the study period before and after administration of Pexuclue tablet.

Conditions

  • Gastroesophageal Reflux Disease

Interventions

DRUG

Fexuprazan

Fexuclue Tablet 40mg

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Principal Investigators

  • Seungyoung Seo · Jeonbuk National University Hospital

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-06
Primary Completion
2023-12-31
Completion
2024-11-08

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05614752 on ClinicalTrials.gov